NABRIVA THERAPEUTICS PLC's ticker is and the CUSIP is G63637105. A total of 20 filers reported holding NABRIVA THERAPEUTICS PLC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $3,000 | 0.0% | 5,500 | 0.0% | 0.00% | – |
| Q2 2020 | $3,000 | +50.0% | 5,500 | +52.0% | 0.00% | – |
| Q1 2020 | $2,000 | -50.0% | 3,619 | +44.8% | 0.00% | – |
| Q4 2019 | $4,000 | -20.0% | 2,500 | 0.0% | 0.00% | – |
| Q3 2019 | $5,000 | +66.7% | 2,500 | +66.7% | 0.00% | – |
| Q2 2019 | $3,000 | -40.0% | 1,500 | -22.1% | 0.00% | – |
| Q1 2019 | $5,000 | +66.7% | 1,925 | 0.0% | 0.00% | – |
| Q4 2018 | $3,000 | -72.7% | 1,925 | -54.5% | 0.00% | – |
| Q3 2018 | $11,000 | -76.6% | 4,230 | -68.8% | 0.00% | – |
| Q2 2018 | $47,000 | -61.2% | 13,539 | -43.7% | 0.00% | – |
| Q1 2018 | $121,000 | -38.9% | 24,030 | -27.2% | 0.00% | – |
| Q4 2017 | $198,000 | -61.1% | 33,030 | -46.9% | 0.00% | – |
| Q3 2017 | $509,000 | -8.0% | 62,202 | +17.8% | 0.00% | – |
| Q2 2017 | $553,000 | – | 52,807 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,074,190 | $33,368,000 | 6.74% |
| Novo Holdings A/S | 2,903,800 | $23,782,000 | 3.10% |
| PURA VIDA INVESTMENTS, LLC | 425,000 | $3,481,000 | 1.02% |
| ACUTA CAPITAL PARTNERS, LLC | 400,000 | $3,276,000 | 0.59% |
| Monashee Investment Management LLC | 188,000 | $1,540,000 | 0.58% |
| Orbimed Advisors | 3,919,600 | $32,102,000 | 0.31% |
| FT Options LLC | 20,000 | $164,000 | 0.25% |
| Rock Springs Capital Management LP | 625,000 | $5,119,000 | 0.24% |
| Rubric Capital Management LP | 300,000 | $2,457,000 | 0.22% |
| Ghost Tree Capital, LLC | 120,000 | $983,000 | 0.21% |